Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Literature
1.
2.
3.
Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.CrossRefPubMed
4.
Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart. 2017;4(2): e000651.CrossRefPubMedPubMedCentral
5.
Gragnano F, Capolongo A, Terracciano F, et al. Escalation and de-escalation of antiplatelet therapy after acute coronary syndrome or PCI: available evidence and implications for practice. J Clin Med. 2022;11(21):6246.CrossRefPubMedPubMedCentral
6.
Gorog DA, Ferreiro JL, Ahrens I, Ako J, et al. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. Nat Rev Cardiol. 2023;20(12):830–44.CrossRefPubMed
7.
Kang J, Kim HS. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and “Asian Paradox.” Korean Circ J. 2018;48(7):537–51.CrossRefPubMedPubMedCentral
8.
Tamargo J, Kaski JC, Kimura T, et al. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events. Eur Heart J Cardiovasc Pharmacother. 2022;8(7):738–51.CrossRefPubMedPubMedCentral
9.
Kuo FY, Lee CH, Lan WR, et al. Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: switch study. J Formos Med Assoc. 2022;121(9):1786–97.CrossRefPubMed
10.
Beitelshees AL, Thomas CD, Empey PE, et al. CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings. J Am Heart Assoc. 2022;11(4): e024159.CrossRefPubMedPubMedCentral
11.
Almendro-Delia M, Blanco-Ponce E, Carmona-Carmona J, et al. Comparative safety and effectiveness of Ticagrelor versus Clopidogrel in patients with acute coronary syndrome: an on-treatment analysis from a multicenter registry. Front Cardiovasc Med. 2022;9: 887748.CrossRefPubMedPubMedCentral
Metadata
Title
Author’s Reply to Kow et al.: “Comparison of Clinical Outcomes between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”
Authors
Hsiu-Yu Fang
Wei-Chieh Lee
Publication date
25-01-2024
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 2/2024
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-023-00627-z

Other articles of this Issue 2/2024

American Journal of Cardiovascular Drugs 2/2024 Go to the issue

Systematic Review

SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis

Review Article

Melatonin: a new agent for treating CVD?

Review Article

Management of Hypertension in the Asia-Pacific Region: A Structured Review

Systematic Review

Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis

Systematic Review

Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis

Original Research Article

Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits